^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ThisCART19A
i
Other names: ThisCART19A, ThisCART19, allogeneic CAR-T targeting CD19, ThisCART19 cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Fundamenta Therap
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
1d
Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. (clinicaltrials.gov)
P1, N=20, Recruiting, The First Affiliated Hospital of Soochow University | Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2026 --> Nov 2025
Enrollment open • Trial primary completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
cyclophosphamide • Nailike (olverembatinib) • fludarabine IV • ThisCART19A
over2years
CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy (clinicaltrials.gov)
P1, N=13, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting
Enrollment open
|
ThisCART19A
over2years
CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy (clinicaltrials.gov)
P1, N=13, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
New P1 trial
|
ThisCART19A
over2years
Intracellular Retention of Tcrαβ/CD3 to Generate Novel Allogeneic CAR-T Cells (ThisCART19A) with Enhanced Antitumor Potency for Treating B-ALL (ASH 2023)
All patients received intravenous fludarabine (30mg/m2/d), cyclophosphamide (300mg/m2/d) and etoposide (100mg/d) for 5 days followed by a single infusion of thisCART19A. We report for the first time that intracellular retention of TCRαβ/CD3 complex can successfully manufacture allogeneic CAR-T cells, with superior activation potential. In patients with R/R B-ALL, ThisCART19A demonstrated acceptable safety, robust expansion and encouraging clinical response profiles. With streamlined single-vector-based production and enhanced CAR signaling, ThisCART platform represents an attractive alternative to gene-editing-based allogeneic CAR-T platforms.
CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
cyclophosphamide • etoposide IV • fludarabine IV • ThisCART19A
3years
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma (clinicaltrials.gov)
P1/2, N=12, Not yet recruiting, Chongqing University Cancer Hospital
New P1/2 trial
|
CD4 (CD4 Molecule)
|
cyclophosphamide • etoposide IV • fludarabine IV • ThisCART19A
over3years
ThisCART19A for B-NHL Relapsed After Auto-CAR T (clinicaltrials.gov)
P1, N=20, Recruiting, The First Affiliated Hospital of Soochow University
New P1 trial
|
CD19 (CD19 Molecule)
|
CD19 positive
|
ThisCART19A
over3years
ThisCART19A Bridging to alloHSCT for R/R B-ALL (clinicaltrials.gov)
P1, N=20, Recruiting, The First Affiliated Hospital of Soochow University
New P1 trial
|
CD19 (CD19 Molecule)
|
CD19 positive
|
ThisCART19A
over3years
Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=19, Not yet recruiting, Fundamenta Therapeutics, Ltd.
New P1 trial
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • JAK2 (Janus kinase 2) • CD19 (CD19 Molecule) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • IKZF1 (IKAROS Family Zinc Finger 1) • JAK1 (Janus Kinase 1) • CD22 (CD22 Molecule) • IL7R (Interleukin 7 Receptor) • TCF3 (Transcription Factor 3) • SH2B3 (SH2B Adaptor Protein 3)
|
CD19 expression
|
cyclophosphamide • etoposide IV • ThisCART19A
almost4years
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma (clinicaltrials.gov)
P1, N=15, Not yet recruiting, Zhengzhou University
New P1 trial
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL17A (Interleukin 17A) • IL22 (Interleukin 22) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
|
BCL6 rearrangement • BCL2 rearrangement
|
ThisCART19A
over4years
Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma (clinicaltrials.gov)
P1, N=20, Recruiting, Fundamenta Therapeutics, Ltd.
Clinical • New P1 trial
|
CD19 (CD19 Molecule)
|
ThisCART19A
Share via
